January 2017

News Back to resource centre 25 January 2017 CANTAB Mobile awarded FDA clearance Cambridge Cognition today announces it has received 510(k) clearance from the U.S. Food and Drug Administration (‘FDA’) to market its CANTAB Mobile product as a medical device in the U.S.Cambridge Cognition today announces it has received 510(k) clearance from the U.S. Food and Drug Administration (‘FDA’) to market CANTAB Mobile as a medical device in the U.S.CANTAB

News Back to resource centre 12 January 2017 Autifony Therapeutics Continues Evaluation of AUT00206 for the Treatment of Schizophrenia Autifony Therapeutics recently presented a poster at the American College of Neuropsychopharmacology following their first human Phase I study in healthy male volunteers to investigate a novel treatment for the positive, negative and cognitive symptoms of schizophrenia.Autifony Therapeutics recently presented a